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Excipient selection and aerodynamic characterization of nebulized lipid-based 
nanoemulsion loaded with docetaxel for lung cancer treatment 
ABSTRACT 
Docetaxel has demonstrated extraordinary anticancer effects on lung cancer. However, lack           
of optimal bioavailability due to poor solubility and high toxicity at its therapeutic dose has               
hampered the clinical use of this anticancer drug. Development of nanoemulsion formulation            
along with biocompatible excipients aimed for pulmonary delivery is a potential strategy to             
deliver this poorly aqueous soluble drug with improved bioavailability and biocompatibility.           
In this work, screening and selection of pharmaceutically acceptable excipients at their            
minimal optimal concentration have been conducted. The selected nanoemulsion         
formulations were prepared using high-energy emulsification technique and subjected to          
physicochemical and aerodynamic characterizations. The formulated nanoemulsion had mean         
particle size and ζ-potential in the range of 90 to 110 nm and − 30 to − 40 mV respectively,                  
indicating high colloidal stability. The pH, osmolality, and viscosity of the systems met the              
ideal requirement for pulmonary application. The DNE4 formulation exhibited slow drug           
release and excellent stability even under the influence of extreme environmental conditions.            
This was further confirmed by transmission electron microscopy as uniform spherical           
droplets in nanometer range were observed after storage at 45 ± 1 °C for 3 months              
indicating high thermal stability. The nebulized DNE4 exhibited desirable aerosolization          
properties for pulmonary delivery application and found to be more selective on human lung              
carcinoma cell (A549) than normal cell (MRC-5). Hence, these characteristics make the            
formulation a great candidate for the potential use as a carrier system for docetaxel in               
targeting lung cancer via pulmonary delivery. 
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